Mentions in the Press
Highlighting Our Clients' Media Coverage

Biotech megadeals: Exploring the surge in $100M+ deals
A month ago Crunchbase published an article titled “Megadeals explode early in the year as U.S. startups gobble up more $100 million+ rounds.” Indeed, with 115 funding rounds surpassing the $100 million mark, the amount of megadeals is already above last year’s 73 deals. Among the startups raising these substantial amounts, biotech and healthcare companies […]
Read Now

Psychedelic Community Reacts To FDA Committee’s Critique Of Lykos’ MDMA Studies
This past week, an FDA advisory committee voted 9-2 to reject the validity of therapy-assisted MDMA clinical trials conducted by Lykos Therapeutics for the treatment of PTSD.
Read Now

Meds For Depression, Anxiety, Addiction Producer Trims Q1 Net Loss YoY, Increases Cash On Hand
As a biotechnology company, Enveric is dedicated to the development of novel neuropathogenic small-molecule therapeutics for the treatment of depression, anxiety and addiction disorders.
Read Now

Finding The Right Patients For Ketamine Clinical Trials
Ketamine can provide relief from mental health conditions in hours. Compare that with the weeks it may take other therapies, and the allure for both providers and their patients is clear.
Read Now

Psychedelics for Depression: MindBio and Enveric’s Joint Efforts
This partnership represents a significant move toward utilizing psychedelic medicines to manage mental health disorders without the typical hallucinogenic effects.
Read Now

Enveric Biosciences to out-license psilocin prodrug to MindBio
Enveric is eligible to receive up to an aggregate of $66.5m in development and sales milestones from MindBio.
Read Now

Major deals continue positive trajectory in 2024
This week saw one of the globe’s top five biggest pharmaceutical companies – AbbVie – enter the market, while Enveric and MindBio signed a $66.5 million deal.
Read Now

Psychedelics Biotech Signs $66.5M Non-Binding Deal To Out-License Novel Psilocin Prodrug Candidate
The news comes on the heels of Enveric entering into a non-binding term sheet with an undisclosed biotech company (licensee) for an exclusive license to two patented methods aimed at treating breast cancer and other cancers.
Read Now

Psychedelics Biotech Inks $61M License Deal For Patented Methods
As per the agreement, the licensee will obtain an exclusive, global license to these methods, along with any devices and drugs developed to implement them.
Read Now

A Pioneering Push in Cancer Treatment: Enveric Biosciences Advances with Cannabinoid Therapies
Enveric Biosciences, a notable player in biotechnological innovations, has recently announced a significant licensing agreement that might change the landscape of cancer treatment.